Sandra Vukusic, Fabien Rollot, Romain Casey, Julie Pique, Romain Marignier, Guillaume Mathey, Gilles Edan, David Brassat, Aurélie Ruet, Jérôme De Sèze, Elisabeth Maillart, Hélène Zéphir, Pierre Labauge, Nathalie Derache, Christine Lebrun-Frenay, Thibault Moreau, Sandrine Wiertlewski, Eric Berger, Xavier Moisset, Audrey Rico-Lamy, Bruno Stankoff, Caroline Bensa, Eric Thouvenot, Olivier Heinzlef, Abdullatif Al-Khedr, Bertrand Bourre, Mathieu Vaillant, Philippe Cabre, Alexis Montcuquet, Abir Wahab, Jean-Philippe Camdessanché, Ayman Tourbah, Anne-Marie Guennoc, Karolina Hankiewicz, Ivania Patry, Chantal Nifle, Nicolas Maubeuge, Céline Labeyrie, Patrick Vermersch, David-Axel Laplaud
Importance: Risk of developing progressive multifocal leukoencephalopathy (PML) is the major barrier to using natalizumab for patients with multiple sclerosis (MS). To date, the association of risk stratification with PML incidence has not been evaluated. Objective: To describe the temporal evolution of PML incidence in France before and after introduction of risk minimization recommendations in 2013. Design, Setting, and Participants: This observational study used data in the MS registry OFSEP (Observatoire Français de la Sclérose en Plaques) collected between April 15, 2007, and December 31, 2016, by participating MS expert centers and MS-dedicated networks of neurologists in France...
January 1, 2020: JAMA Neurology